Compare Illumina, Inc. (ILMN) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nvidia Corp — how do they compare? Illumina, Inc. trades at $278.09 (market cap $39.95B), while Nvidia Corp trades at $229.44 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 139.4× Illumina, Inc.'s market cap, and Nvidia Corp pays a 0.43% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Nvidia Corp for 115 Days on average.
| ILMN | NVDA | |
|---|---|---|
Market Cap | $39.95B | $5.57T |
Volume | 3,169,503 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $293.69 | $239.27 |
52-Week Low | $91.00 | $165.17 |
Typical Hold Time | 83 Days | 115 Days |
Enterprise Value | $41.31B | $5.54T |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
NVIDIA (NVDA) trades at $229.28, down 3.4% today, but maintains strong fundamentals with revenue surging to $130.5B in 2025 and net income reaching $72.88B. The stock shows a bullish technical signal with support at $228 and resistance at $235. Recent earnings beats and a 75.95% analyst buy rating highlight continued growth momentum despite the day's decline.
Outlook remains positive with a consensus price target of $339.17, offering 48% upside. Key risks include increased competition in AI chips and market volatility, but NVIDIA's dominant market position and accelerating AI demand support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
